Loading
Lisata Therapeutics
Lisata is a New Jersey biotech developing certepetide, a peptide that opens up the dense stroma of pancreatic tumours so chemotherapy can reach the cancer cells; it is tested with gemcitabine and nab-paclitaxel.
Also called: Lisata Therapeutics, Inc.Caladrius BiosciencesCend Therapeutics
Overview
Lisata Therapeutics, formed when Caladrius Biosciences merged with Cend Therapeutics in 2022 and based in Basking Ridge, New Jersey, develops certepetide (LSTA1, formerly CEND-1), a cyclic peptide that binds alpha-v integrins and neuropilin-1 to increase drug penetration into solid tumours. It is tested in metastatic pancreatic cancer with standard chemotherapy and in other stroma-rich tumours, registered on ClinicalTrials.gov under Lisata as lead sponsor.
Connected
3Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
- CompanyJW Pharmaceutical
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
lisata.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/